neutrophil trang 8 tải miễn phí từ TAILIEUCHUNG

"neutrophil" trang 8 - tải miễn phí từ Tailieuchung

Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1–2 rectal cancer

Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1–2 rectal cancer

11 80 0

Combination of preoperative neutrophillymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: A superior prognostic factor of endometrial cancer

Combination of preoperative neutrophillymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: A superior prognostic factor of endometrial cancer

11 84 0

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: Pooled subgroup analysis from the randomized, COMPARZ studies

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: Pooled subgroup analysis from the randomized, COMPARZ studies

8 49 0

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

8 94 0

Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy

Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy

9 67 0

The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsybased Gleason score ≤ 6

The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsybased Gleason score ≤ 6

8 25 1

A novel combined systemic inflammationbased score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

A novel combined systemic inflammationbased score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

9 31 1

Prognostic value of systemic inflammatory markers in ovarian Cancer: A PRISMAcompliant meta-analysis and systematic review

Prognostic value of systemic inflammatory markers in ovarian Cancer: A PRISMAcompliant meta-analysis and systematic review

10 35 1

New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer

New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer

9 51 1

Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients

Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients

14 19 1

Hematologic markers of distant metastases and poor prognosis in gynecological cancers

Hematologic markers of distant metastases and poor prognosis in gynecological cancers

8 25 1

The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: A retrospective study

The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: A retrospective study

8 30 1

Predictive value of lymphocyte-tomonocyte ratio in the preoperative setting for progression of patients with breast cancer

Predictive value of lymphocyte-tomonocyte ratio in the preoperative setting for progression of patients with breast cancer

9 21 1

Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer

Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer

10 30 1

Belotecan/cisplatin versus etoposide/ cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: A multi-center randomized phase III trial

Belotecan/cisplatin versus etoposide/ cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: A multi-center randomized phase III trial

9 43 1

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

7 56 1

Prognostic value of CD66b positive tumorinfiltrating neutrophils in testicular germ cell tumor

Prognostic value of CD66b positive tumorinfiltrating neutrophils in testicular germ cell tumor

7 52 1

Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and nonoropharyngeal patients

Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and nonoropharyngeal patients

13 31 1

Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma

Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma

11 19 1

A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: The C-reactive protein/albumin ratio

A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: The C-reactive protein/albumin ratio

11 17 1

Đầu
1
2
3
4
5
6
7
[ 8 ]
9
10
11
Cuối

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.